Risk of Peptic Ulcer Bleeding Associated with Helicobacter pylori Infection, Nonsteroidal Anti-inflammatory Drugs, and Low-dose Aspirin Therapy in Peptic Ulcer Disease: A Case-control Study

다국어 초록 (Multilingual Abstract)

Background/Aims: The association between Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin therapy as a risk factor for peptic ulcer bleeding (PUB) remains unclear. This study investigated the risk of PUB associated with H. pylori infection and NSAID or low-dose aspirin therapy in patients with PUD. Materials and Methods: This case-control study investigated 340 patients with PUB between 2012 and 2016. The control group comprised age and sex-matched patients with endoscopically documented non-bleeding ulcers. Using logistic regression analysis, the adjusted odds ratio (AOR) was calculated for the risk of PUB. Results: Of the patients investigated, 57.9% in the study group and 51.8% in the control group were diagnosed with H. pylori infection (P=0.106). Logistic regression analysis showed synergistic interaction between H. pylori infection and low-dose aspirin therapy. Multivariate analysis showed that low-dose aspirin (AOR 3.92, P＜0.001), NSAIDs (AOR 2.98, P=0.001), warfarin (AOR 14.57, P=0.011), gastric ulcer (compared with duodenal ulcer) (AOR 1.65, P=0.01), and smoking (AOR 1.97, P=0.004) increased the risk of PUB compared with the risk of PUD. Conclusions: Both NSAIDs and aspirin are independent risk factors for bleeding in patients with PUD. Additionally, low-dose aspirin therapy concomitant with H. pylori infection produced a synergistic effect. Therefore, H. pylori eradication may be crucial in aspirin users. Moreover, a proton pump inhibitor should be prescribed in patients with a history of bleeding ulcers who need long-term NSAID treatment. (Korean J Helicobacter Up Gastrointest Res 2019;19:42-47)

참고문헌 (Reference)

1 김상균, "한국인 헬리코박터 파일로리 감염의 진단과 치료 임상 진료지침 개정안 2013" 대한소화기학회 62 (62): 3-26, 2013

2 고진성, "약제 유발 소화성궤양에서 Helicobacter pylori 감염의 역할" 대한상부위장관ㆍ헬리코박터학회 18 (18): 89-94, 2018

3 Sánchez-Delgado J, "pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression" 106 : 398-405, 2011

4 Sung JJ, "Systematic review : the global incidence and prevalence of peptic ulcer disease" 29 : 938-946, 2009

5 Fletcher EH, "Systematic review : Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin" 32 : 831-839, 2010

6 Fock KM, "Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection" 24 : 1587-1600, 2009

7 Huang JQ, "Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease : a meta-analysis" 359 : 14-22, 2002

8 Nagata N, "Risk of peptic ulcer bleeding associated with Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs, low-dose aspirin, and antihypertensive drugs : a case-control study" 30 : 292-298, 2015

9 Kang JM, "Risk factors for peptic ulcer bleeding in terms of Helicobacter pylori, NSAIDs, and antiplatelet agents" 46 : 1295-1301, 2011

10 Barr M, "Review article : non-steroidal anti-inflammatory drugs and Helicobacter pylori" 14 (14): 43-47, 2000

11 Okan A, "Relationship between non-steroidal anti-inflammatory drug use and Helicobacter pylori infection in bleeding or uncomplicated peptic ulcers : a case-control study" 18 : 18-25, 2003

12 Sostres C, "Peptic ulcer bleeding risk. The role of Helicobacter pylori infection in NSAID/low-dose aspirin users" 110 : 684-689, 2015

13 Vergara M, "Meta-analysis : role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users" 21 : 1411-1418, 2005

14 Malfertheiner P, "Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report" 66 : 6-30, 2017

15 Kawasaki K, "Low-dose aspirin and non-steroidal anti-inflammatory drugs increase the risk of bleeding in patients with gastroduodenal ulcer" 60 : 1010-1015, 2015

16 Leung Ki EL, "Interaction of Helicobacter pylori infection and low-dose aspirin in the upper gastrointestinal tract : implications for clinical practice" 26 : 163-172, 2012

17 Sostres C, "Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use : old question new insights" 20 : 9439-9450, 2014

18 Hawkey CJ, "Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users" 51 : 344-350, 2002

19 Jang HJ, "Has peptic ulcer disease changed during the past ten years in Korea? A prospective multi-center study" 53 : 1527-1531, 2008

20 Sostres C, "Epidemiology and demographics of upper gastrointestinal bleeding : prevalence, incidence, and mortality" 21 : 567-581, 2011

21 Papatheodoridis GV, "Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease : a systematic review" 4 : 130-142, 2006

22 Sakamoto C, "Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan" 62 : 765-772, 2006

23 Choi YJ, "Accuracy of diagnostic tests for Helicobacter pylori in patients with peptic ulcer bleeding" 17 : 77-85, 2012

24 Chey WD, "ACG Clinical Guideline : treatment of Helicobacter pylori infection" 112 : 212-239, 2017